Artwork

Contenido proporcionado por Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen). Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen) o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Player FM : aplicación de podcast
¡Desconecta con la aplicación Player FM !

#1 Sustaining A Rare Disease Pipeline with Rocket Pharma

23:58
 
Compartir
 

Manage episode 425269218 series 3580422
Contenido proporcionado por Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen). Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen) o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In this episode of "Rare Insights," host Taren Grom sits down with Dr. Kinnari Patel, President, Head of R&D and Chief Operating Officer for Rocket Pharma, to discuss the company’s burgeoning pipeline of rare disease assets and why applying data across its portfolio of potential treatments is just one key to the company’s success.

Dr. Kinnari Patel is President, Head of R&D, and Chief Operating Officer for Rocket Pharma, overseeing the global R&D and Technical Operations leadership team with oversight spanning discovery through late-stage development and manufacturing. This includes regulatory, clinical, global program teams, CMC, quality and the development organization. Dr. Patel’s prior responsibilities at Rocket included IR, IT, HR, finance and corporate compliance. Dr. Patel has more than 20 years of R&D experience in rare diseases and across several therapeutic areas including immuno-oncology, oncology, respiratory, virology, transplantation, cardiology and metabolism.

Discussion Topics:

  1. Advancing the company’s six rare disease assets: Dr. Patel provides an update on Rocket’s pipeline.

  1. Update on Kresladi: Insights into marnetegragene autotemcel’s progress from IND to BLA for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I) in fewer than five years.

  1. Bringing down the risk of drug development: Dr. Patel reflects on how the company’s experience and operational expertise of taking a platform portfolio approach is helping to advance the pipeline.

  1. A culture of patient focus: Building trusted relationships with everyone involved, learning how to be generous with knowledge, and being curious are keys to Rocket’s success.

  1. The rare disease space looking forward: Dr. Patel identifies several trends she hopes will impact patients — doubling or tripling the number of gene therapies approved, bringing down the cost of developing gene therapies, and making rare disease therapies available to communities around the world.

Stay tuned for the next episode of Rare Insights in July! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “Rare Insights”.

Rare Insights’ team includes Taren Grom, Liz Kay, Kaitlyn Wosik, DNA Today’s Kira Dineen, and

myself, Nina Wachsman.

See what else we are up to on X, Instagram, Facebook, YouTube, and our website, knowrare.com. Questions/inquiries can be sent to podcast@knowrare.com.

  continue reading

2 episodios

Artwork
iconCompartir
 
Manage episode 425269218 series 3580422
Contenido proporcionado por Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen). Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen), Know Rare (Taren Grom, Liz Kay, Kaitlyn Taylor, Nina Wachsman, and DNA Today’s Kira Dineen) o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.

In this episode of "Rare Insights," host Taren Grom sits down with Dr. Kinnari Patel, President, Head of R&D and Chief Operating Officer for Rocket Pharma, to discuss the company’s burgeoning pipeline of rare disease assets and why applying data across its portfolio of potential treatments is just one key to the company’s success.

Dr. Kinnari Patel is President, Head of R&D, and Chief Operating Officer for Rocket Pharma, overseeing the global R&D and Technical Operations leadership team with oversight spanning discovery through late-stage development and manufacturing. This includes regulatory, clinical, global program teams, CMC, quality and the development organization. Dr. Patel’s prior responsibilities at Rocket included IR, IT, HR, finance and corporate compliance. Dr. Patel has more than 20 years of R&D experience in rare diseases and across several therapeutic areas including immuno-oncology, oncology, respiratory, virology, transplantation, cardiology and metabolism.

Discussion Topics:

  1. Advancing the company’s six rare disease assets: Dr. Patel provides an update on Rocket’s pipeline.

  1. Update on Kresladi: Insights into marnetegragene autotemcel’s progress from IND to BLA for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I) in fewer than five years.

  1. Bringing down the risk of drug development: Dr. Patel reflects on how the company’s experience and operational expertise of taking a platform portfolio approach is helping to advance the pipeline.

  1. A culture of patient focus: Building trusted relationships with everyone involved, learning how to be generous with knowledge, and being curious are keys to Rocket’s success.

  1. The rare disease space looking forward: Dr. Patel identifies several trends she hopes will impact patients — doubling or tripling the number of gene therapies approved, bringing down the cost of developing gene therapies, and making rare disease therapies available to communities around the world.

Stay tuned for the next episode of Rare Insights in July! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “Rare Insights”.

Rare Insights’ team includes Taren Grom, Liz Kay, Kaitlyn Wosik, DNA Today’s Kira Dineen, and

myself, Nina Wachsman.

See what else we are up to on X, Instagram, Facebook, YouTube, and our website, knowrare.com. Questions/inquiries can be sent to podcast@knowrare.com.

  continue reading

2 episodios

Kaikki jaksot

×
 
Loading …

Bienvenido a Player FM!

Player FM está escaneando la web en busca de podcasts de alta calidad para que los disfrutes en este momento. Es la mejor aplicación de podcast y funciona en Android, iPhone y la web. Regístrate para sincronizar suscripciones a través de dispositivos.

 

Guia de referencia rapida